37 patents
Page 2 of 2
Utility
Factor IX Polypeptide Mutant, Its Uses and a Method for Its Production
15 Jul 21
Disclosed are a modified FIX (Factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
Paolo SIMIONI
Filed: 26 Mar 21
Utility
Mutated rep encoding sequences for use in AAV production
13 Jul 21
Nucleic acids encoding Parvoviral Rep proteins with a mutated nuclear localization signal (NLS) are provided.
Yvet Noordman, Jacek Lubelski, Andrew Christian Bakker
Filed: 17 Jul 19
Utility
Immunoadsorption
15 Jun 21
Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome.
Valerie Ferreira
Filed: 15 Apr 19
Utility
DNA impurities in a composition comprising a parvoviral virion
1 Jun 21
The current invention relates to nucleic acid impurities in a composition comprising a parvoviral vector.
Jacek Lubelski, Wilhelmus Theodorus Johannes Maria Christiaan Hermens
Filed: 27 Nov 15
Utility
Vectors with Modified Initiation Codon for the Translation of AAV-REP78 Useful for Production of Aav
20 May 21
The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions.
Wilhelmus Johannes Theodorus Maria Christiaan Hermens, Saskia Jacoba Petronella Haast, Dennis Johan Biesmans, Andrew Christian Bakker
Filed: 14 Dec 20
Utility
Vectors with modified initiation codon for the translation of AAV-REP78 useful for production of AAV
14 Dec 20
The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions.
Wilhelmus Theodorus Johannes Maria Christiaan Hermens, Saskia Jacoba Petronella Haast, Dennis Johan Biesmans, Andrew Christian Bakker
Filed: 9 Jan 20
Utility
Methods of Improving Adeno-associated Viral Transduction
18 Nov 20
Described herein are saturating agents, AAV gene therapy vectors, and therapeutic agents, as well as methods and kits comprising the same.
Valerie FERREIRA
Filed: 8 Jun 20
Utility
Further improved AAV vectors produced in insect cells
16 Nov 20
The present invention relates to the production of adeno-associated viral vectors in insect cells.
Jacek Lubelski, Sebastiaan Menno Bosma, Harald Peter Albert Petry, Wilhelmus Theodorus Johannes Maria Christiaan Hermens
Filed: 9 Mar 15
Utility
RNAi Induced Huntingtin Gene Suppression
28 Oct 20
The present invention provides for a double stranded RNA comprising a first RNA sequence and a second RNA sequence wherein the first and second RNA sequence are substantially complementary, wherein the first RNA sequence has a sequence length of at least 19 nucleotides and is substantially complementary to SEQ ID NO. 1.
Pavlina Stefanova KONSTANTINOVA, Jana MINIARIKOVÁ
Filed: 14 Jul 20
Utility
Modified Viral Vectors and Methods of Making and Using the Same
14 Oct 20
The present invention relates to production of parvoviral vectors to produce adeno-associated virus (AAV) for gene therapy.
David Johannes Francois DU PLESSIS
Filed: 23 Jun 20
Utility
RNAi induced huntingtin gene suppression
7 Sep 20
The present invention provides for a double stranded RNA comprising a first RNA sequence and a second RNA sequence wherein the first and second RNA sequence are substantially complementary, wherein the first RNA sequence has a sequence length of at least 19 nucleotides and is substantially complementary to SEQ ID NO. 1.
Pavlina Stefanova Konstantinova, Jana Miniariková
Filed: 15 Nov 18
Utility
Aav Capsid Production In Insect Cells
5 Aug 20
The present invention relates to the production of adeno-associated viral vectors in insect cells.
David Johannes Francois Du Plessis, Olivier Ter Brake, Sebastiaan Menno Bosma, Harald Peter Albert Petry, Jacek Lubelski
Filed: 14 Jan 20
Utility
Factor IX Polypeptide Mutant, Its Uses and a Method for Its Production
22 Jul 20
Disclosed are a modified FIX (Factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
Paolo SIMIONI
Filed: 30 Sep 19
Utility
Factor IX Polypeptide Mutant, Its Uses and a Method for Its Production
24 Jun 20
Disclosed are a modified FIX (Factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
Paolo SIMIONI
Filed: 10 Feb 20
Utility
RNAi induced reduction of ataxin-3 for the treatment of Spinocerebellar ataxia type 3
24 Jun 20
The current invention relates to gene therapy approaches for the treatment of SCA3, in particular RNAi based gene therapy approaches utilizing a total knockdown approach.
Melvin Maurice EVERS, Pavlina Stefanova KONSTANTINOVA, Raygene Michael MARTIER
Filed: 13 Nov 19
Utility
Factor IX Polypeptide Mutant, Its Uses and a Method for Its Production
17 Jun 20
Disclosed are a modified FIX (Factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
Paolo SIMIONI
Filed: 8 Dec 19
Utility
Vectors with Modified Initiation Codon for the Translation of AAV-REP78 Useful for Production of Aav
29 Apr 20
The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions.
Wilhelmus Theodorus Johannes Maria Christiaan Hermens, Saskia Jacoba Petronella Haast, Dennis Johan Biesmans, Andrew Christian Bakker
Filed: 9 Jan 20